NCT00983801 - Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Stomach Neoplasms

Interventions

DRUG

Ixabepilone

Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.

Trial Locations (9)

112

Local Institution, Taipei

333

Local Institution, Taoyuan Hsien

169610

Local Institution, Singapore

4118777

Local Institution, Sunto-Gun

4648681

Local Institution, Nagoya

B

Local Institution, Hong Kong

135-710

Local Institution, Seoul

136-705

Local Institution, Seoul

138-736

Local Institution, Seoul